TuHURA Biosciences, Inc.
$2.27
+9.4%TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, FL.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -3.6).
Valuation inputs: P/E -3.6, earnings yield N/A, momentum +9.4%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -1.4%, ROIC -1.5%).
Profitability stack: net margin 0.0%, ROE -1.4%, ROIC -1.5%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +23.5%, momentum +9.4%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
TuHURA Biosciences, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
TuHURA Biosciences, Inc. Fair Value Envelope
No Revenue Data
HURA has not reported any revenue values in the available annual periods.
TuHURA Biosciences, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
HURA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
HURA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
HURA has not reported any net profit margin values in the available annual periods.
TuHURA Biosciences, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
TuHURA Biosciences, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Acceptable liquidity, but monitor closely. Current assets just barely cover current liabilities.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Positive working capital, but relatively tight. The company should monitor cash flow carefully.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.
TuHURA Biosciences, Inc. Street Expectations Map
No Target Data
No analyst price targets available for hura.
TuHURA Biosciences, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for HURA.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
hura Dividend History
Learning Layer
Related Guides
Build conviction on HURA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.